02 November 2021


Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor

Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors. Tom is a seasoned financial executive bringing a wealth of global experience that spans corporate development, commercial strategy, portfolio management, and value creation for both public and private biopharmaceutical companies.

Tom Graney has over 25 years’ diverse and rich experience in biopharma. His industry experience comprises time spent as CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio after a long career at Johnson & Johnson, which includes four years as worldwide Vice President of Finance and CFO of Ethicon. Most recently, he has been appointed CEO-CFO of Oxurion (EBR: OXUR), a clinical-stage biopharmaceutical company developing next-generation ophthalmic therapies. To date, he has contributed towards the raising of more than $500 Million USD on both private and public capital markets. A Chartered Financial Analyst, Certified Financial Manager and Management Accountant, Graney holds a BS in accounting from the University of Delaware and an MBA in Marketing, Finance and International Business from the Leonard N. Stern School of Business at New York University.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “We are honored to welcome Tom to the Board of Directors following the recent appointment of Dr. Louise Modis as CSO. His appointment further strengthens our leadership team, which includes industry leaders in platform technologies, drug development and biopharma company building. Tom joins us after many months of ongoing support which is a testament to his dedication to nurturing innovation towards impactful medicines for patients.

Tom’s considerable experience in both public and private settings, expertise in financial planning and structuring and knowledge of US capital markets will allow Mogrify to strengthen its position in the lead up to cross-over funding rounds and ultimately, an IPO.”

Tom Graney, CFA, Board member, Mogrify, added: “I am delighted to be joining Mogrify which has shown enormous progress over the past 12 months. The Company’s innovative suite of cellular reprogramming and delivery technologies hold unique and scalable potential to underpin the development of novel in vivo and ex vivo treatments for patients with few alternatives.

I am looking forward to working with the world-class team as they translate this deep expertise in cellular reprogramming into the advancement of internal programs in ophthalmology, immuno-oncology and other disease areas through to first-in-human studies”.

For further information about Mogrify’s team, please visit:

Notes to Editors

Darrin M. Disley OBE, CEO, Mogrify

Darrin M. Disley, PhD, DSc, OBE CEO, Mogrify

Louise Modis, Chief Scientific Officer

Tom Graney, CFA
Board member, Mogrify

For high-resolution and alternate images please contact Zyme Communications

Mogrify Contacts
Darrin M. Disley, PhD, OBE
Tel: + 44 (0)1223 734154
Email: [email protected]

Zyme Communications (media inquiries)
Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: [email protected]

Westwicke, an ICR Company (investor inquiries)
Stephanie Carrington
Tel: +1 (646) 277-1282
Email: [email protected]

About Mogrify

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY™, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors (or small molecules) and optimal culture conditions required to produce any target human cell type from any source human cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct trans differentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to pioneer a new class of in vivo reprogramming therapies and transform the development of ex vivo cell therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner, and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify